Antibody-drug conjugates hitting this target abound.
ApexOnco Front Page
Recent articles
Arvinas and Pfizer abandon first-line atirmociclib combo plans only disclosed in January.
Meanwhile, Akeso challenges Moderna and BioNTech with an mRNA neoantigen play.
The group could soon provide clarity on CTX112’s regulatory path.
The THIO-104 study listing is live, along with questions about funding the trial.
Against the odds, the CD47 inhibitor now faces two more clinical catalysts.
Golcadomide will begin a new pivotal trial in follicular lymphoma.
The private US biotech features among recent first-in-human study entrants, with another PARP1-selective molecule.
